---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-22-000089"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:35:54.281842+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q2 net loss $41.3M; cuts 15% workforce, extends cash runway to 2024

## Summary
- Net loss $41.3M vs $39.9M YoY; cash $133.7M at June 30, plus $34.5M in July payments from partners.
- Workforce reduction of ~15% and closure of Brisbane and Rockville sites to reduce costs.
- Received $30M milestone from Incyte; $60M milestone due upon teplizumab approval (PDUFA Nov 17, 2022).
- Plan to start MGC018 Phase 2/3 TAMARACK study in mCRPC by year-end; interim data from Phase 2 by end 2024.
- Lorigerlimab Phase 1/2 enrollment complete; data update expected early 2023.

## SEC filing metadata
- accession: 0001125345-22-000089
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000089/0001125345-22-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000089/mgnx-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-22-000089
- JSON: https://secwatch.observer/filing/0001125345-22-000089.json
- Plain text: https://secwatch.observer/filing/0001125345-22-000089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.